By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo

TheMediTary.Com

Medical Information, Documents, News - TheMediTary.Com

  • Home
  • News
  • Drugs
  • Drugs A-Z
  • Medical Answers
  • About Us
  • Contact
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo
Search Drugs
  • Drugs
    • Latest Drugs
    • Drugs A-Z
    • Medical Answers
  • News
    • FDA Alerts
    • Medical News
    • Health
    • Consumer Updates
    • Children's Health
  • More TheMediTary.Com
    • About Us
    • Contact
Follow US
Home > Drugs > Angiotensin Converting Enzyme Inhibitors > Ramipril > Ramipril Dosage
Angiotensin Converting Enzyme Inhibitors
https://themeditary.com/dosage-information/ramipril-dosage-6533.html

Ramipril Dosage

Drug Detail:Ramipril (Ramipril [ ram-i-pril ])

Drug Class: Angiotensin Converting Enzyme Inhibitors

Contents
Uses Warnings Before Taking Dosage Side effects Interactions

Usual Adult Dose for Hypertension

Initial dose: 2.5 mg orally once a day for patients not taking a diuretic

Maintenance dose: 2.5 to 20 mg/day in one or two equally divided doses

Comments:

  • Adjust dose according to blood pressure response.
  • The antihypertensive effect may diminish toward the end of a once daily dosing interval; consider increasing dose or twice daily administration.
  • If blood pressure is not controlled with this drug alone, a diuretic may be added.

Use: Treatment of hypertension, to lower blood pressure, alone or in combination with a thiazide diuretic.

Usual Adult Dose for Congestive Heart Failure

Initial dose: 2.5 mg orally twice a day

Maintenance dose: 5 mg orally twice a day

Comments:

  • If possible, decrease concomitant diuretic dose to reduce likelihood of hypotension.
  • After first initial dose, observe at least two hours and until blood pressure has stabilized at least an additional hour.
  • If patient becomes hypotensive on initial dose, reduce to 1.25 mg twice a day.
  • After one week on initial dose, increase toward maintenance dose as tolerated; may increase about every 3 weeks.
  • Initial hypotension does not preclude subsequent titration with this drug, following effective hypotension management.

Use: Treatment of stable patients who have demonstrated clinical signs of congestive heart failure within the first few days after sustaining acute myocardial infarction.

Usual Adult Dose for Cardiovascular Risk Reduction

Initial dose: 2.5 mg orally once a day for one week; 5 mg orally once a day for next three weeks, then increase as tolerated

Maintenance dose: 10 mg orally once a day

Comments:

  • If patient is hypertensive or recently post myocardial infarction, may administer in divided doses.

Use: Reduce the risk of myocardial infarction, stroke, or death from cardiovascular causes in patients 55 years or older at high risk of developing a major cardiovascular event because of a history of coronary artery disease, stroke, peripheral vascular disease, or diabetes that is accompanied by at least one other cardiovascular risk factor (hypertension, elevated total cholesterol levels, low high-density lipoprotein (HDL) levels, cigarette smoking, or documented microalbuminuria); can be used in addition to other needed treatment such as antihypertensive, antiplatelet, or lipid lowering therapy.

Renal Dose Adjustments

CrCl 40 mL/min or less: Reduce usual dose by 25%

CrCl less than 90 mL/min and hypertension: Initial dose: 1.25 mg orally once a day; may titrate up until blood pressure controlled or to maximum dose of 5 mg/day.

CrCl less than 90 mL/min and heart failure: Initial dose: 1.25 mg orally once a day; may increase to 1.25 mg twice daily and to maximum dose of 2.5 mg twice daily.

Renal artery stenosis: Initial dose: 1.25 mg orally once a day

Liver Dose Adjustments

Data not available

Dose Adjustments

Volume depletion (e.g., past and current diuretic use):

  • Initial dose: 1.25 mg orally once a day

Precautions

US BOXED WARNING:

  • FETAL TOXICITY: When pregnancy is detected, discontinue this drug as soon as possible. Drugs that act directly on the renin angiotensin system (RAS) can cause injury and death to the developing fetus.

Safety and efficacy have not been established in patients younger than 18 years.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice:

  • Capsules may be opened and sprinkled in 4 ounces of applesauce, apple juice, or water; mixture may be stored 24 hours at room temperature or 48 hours refrigerated.

Monitoring:
  • Monitor serum potassium periodically.
  • In hypertensive patients with unilateral or bilateral renal artery stenosis, monitor renal function during the first few weeks of therapy.
  • Consider monitoring white blood cells in patients with collagen vascular disease, especially if associated with renal impairment.

Frequently asked questions

  • Do ACE inhibitors make COVID-19 worse?
Share this Article
Latest News
Medical News

Shingles vaccine may lower heart disease risk by up to 8 years

May 09, 2025
Obesity, unhealthy lifestyles may cause heart to age by 5–45 years
Aging: As little as 5 minutes of exercise may keep the brain healthy
Prostate cancer: Simple urine test may help with early detection
Cancer treatment side effects: Exercise may reduce pain, fatigue
Alzheimer's: Exercising in middle age may reduce beta-amyloid in brain...
Related Drugs
Fidanacogene Elaparvovec
Cerave Anti-Itch
Centrum Adult
Crovalimab
Cyltezo Prefilled Syringe
Zepbound Pen
Mylanta One
Uretron Ds
Medihoney Wound And Burn Dressing
Lidotrode

Other drugs

Name Drug Class Updated
Fidanacogene Elaparvovec Drugs 03-Oct-2024
Cerave Anti-Itch Drugs 02-Oct-2024
Centrum Adult Drugs 02-Oct-2024
Crovalimab Drugs 02-Oct-2024
Cyltezo Prefilled Syringe Drugs 01-Oct-2024
Zepbound Pen Drugs 30-Sep-2024
Mylanta One Drugs 27-Sep-2024
Uretron Ds Drugs 27-Sep-2024
Medihoney Wound And Burn Dressing Drugs 26-Sep-2024
Lidotrode Drugs 26-Sep-2024
Libervant Drugs 26-Sep-2024
Moderna Covid-19 Drugs 25-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024

Categories

  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health

About US

Welcome to TheMediTary.Com

Our website provides reliable and up-to-date information on various medical topics. We empower individuals to take charge of their health by simplifying complex medical jargon and providing practical tips and advice. We prioritize the privacy and confidentiality of our users and welcome feedback to improve our services.

Website use data of FDA and other sources

DMCA.com Protection Status Truste Protection Status Trust Mark Protection Status
HONcode logo We comply with the HONcode standard for trustworthy health information.
Quick Link
  • About Us
  • Contact Us
  • Editorial Policy
  • Privacy Policy
  • Accessibility Policy
  • Terms & Conditions
  • Disclaimer
  • DMCA
  • Do Not Sell My Personal Information
  • Sitemap
  • Care Notes
  • Health Guide
  • Professional
Drugs
  • New Drugs
  • Medical Answers
  • Drugs A-Z
  • Drug Classes
  • Drug Dosage
  • Pill Identifier
  • Consumer Infor
  • Side Effects
  • Inactive Ingredients
  • Pregnancy Warnings
  • Patient Tips
  • Treatments
News
  • Latest News
  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health
Find US
  • Medium
  • Google Site
  • Blogspot
  • API
  • Reddit
  • Tumblr
  • Scoop.it
  • Substack
  • Wordpress
  • Wix
  • Behance

© 2025 TheMediTary.Com All rights reserved. Operated by